Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives

2016 ◽  
Vol 63 ◽  
pp. 34-40 ◽  
Author(s):  
Eric L. Staals ◽  
Stefano Ferrari ◽  
Davide M. Donati ◽  
Emanuela Palmerini
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Current Treatment ◽  
Cell Tumour ◽  
Diffuse Type ◽  
Future Perspectives ◽  
Treatment Concepts ◽  
Tenosynovial Giant Cell Tumour

scholarly journals Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
A Righi ◽  
M Gambarotti ◽  
M Sbaraglia ◽  
T Frisoni ◽  
D Donati ◽  
...  
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Pigmented Villonodular Synovitis ◽  
Cell Tumour ◽  
Villonodular Synovitis ◽  
Diffuse Type ◽  
Tenosynovial Giant Cell Tumour ◽  
Pigmented Villonodular

Inconclusive benefit of adjuvant 90Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee

2018 ◽  
Vol 100-B (7) ◽  
pp. 984-988 ◽  
Author(s):  
Y. Gortzak ◽  
M. Vitenberg ◽  
T. Frenkel Rutenberg ◽  
Y. Kollender ◽  
S. Dadia ◽  
...  
Keyword(s):  
Giant Cell ◽  
Adjuvant Treatment ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Diffuse Type ◽  
Musculoskeletal Tumor Society ◽  
Group A ◽  
Tenosynovial Giant Cell Tumour ◽  
Group B

Aims Intra-articular 90Yttrium (90Y) is an adjunct to surgical treatment by synovectomy for patients with diffuse-type tenosynovial giant-cell tumour (dtTGCT) of the knee, with variable success rates. Clinical information is, however, sparse and its value remains unclear. We investigated the long-term outcome of patients who underwent synovectomy with and without adjuvant treatment with 90Yttrium. Patients and Methods All patients with dtTGCT of the knee who underwent synovectomy between 1991 and 2014 were included in the study. Group A patients underwent synovectomy and an intra-articular injection of 90Yttrium between six and eight weeks after surgery. Group B patients underwent surgery alone. Results There were 34 patients in group A and 22 in group B. Recurrence of dtTGCT was identified by MRI, which was undertaken in patients with further symptoms. At a mean follow-up of 7.3 years (2.5 to 25.4), there was residual disease in 15 patients in group A and 11 in group B (p < 0.363). The mean Musculoskeletal Tumor Society (MSTS) score at final follow-up was 85% and 83%, respectively (p < 0.91). Conclusion There were no significant differences in outcome between patients treated surgically for dtTGCT of the knee with or without an adjuvant intra-articular injection of 90Yttrium. We were unable to provide conclusive evidence of any benefits derived from the adjuvant treatment. Cite this article: Bone Joint J 2018;100-B:984–8.

scholarly journals Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour

2020 ◽  
Vol 141 ◽  
pp. 162-170
Author(s):  
Philippe A. Cassier ◽  
Antoine Italiano ◽  
Carlos Gomez-Roca ◽  
Christophe Le Tourneau ◽  
Maud Toulmonde ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Clinical Activity ◽  
Diffuse Type ◽  
Patient Reported ◽  
Tenosynovial Giant Cell Tumour

Destruction of the glenoid joint fossa by a tenosynovial giant-cell tumour of the skull base: a case report

1999 ◽  
Vol 28 (2) ◽  
pp. 132-134 ◽  
Author(s):  
S. Stojadinovic ◽  
S. Reinert ◽  
U. Wildforster ◽  
G. Jundt
Keyword(s):  
Case Report ◽  
Skull Base ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Tenosynovial Giant Cell Tumour

Extra-articular diffuse tenosynovial giant cell tumour of the infratemporal fossa: report of a case and literature review

2010 ◽  
Vol 39 (8) ◽  
pp. 820-824 ◽  
Author(s):  
Z.-c. Gong ◽  
Z.-q. Lin ◽  
A. Moming ◽  
B. Ling ◽  
H. Liu ◽  
...  
Keyword(s):  
Literature Review ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Infratemporal Fossa ◽  
Cell Tumour ◽  
Tenosynovial Giant Cell Tumour

scholarly journals RECURRENT GIANT CELL TUMOUR OF THE FLEXOR TENDON SHEATH OF THE DISTAL PALM – A CASE REPORT

2020 ◽  
pp. 1-2
Author(s):  
Surya Rao Rao Venkata Mahipathy ◽  
Alagar Raja Durairaj ◽  
Narayanamurthy Sundaramurthy ◽  
Anand Prasath Jayachandiran ◽  
Volga Harikrishnan
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Flexor Tendon ◽  
Imaging Modality ◽  
Benign Lesion ◽  
Tendon Sheath ◽  
Cell Tumour ◽  
Recurrence Rates ◽  
Flexor Tendon Sheath ◽  
Tenosynovial Giant Cell Tumour

Giant cell tumor of the tendon sheath is a common benign lesion of the hand. They are also known as tenosynovial giant cell tumours. Magnetic resonance imaging is the imaging modality of choice and the current treatment is surgical excision of the lesion. This lesion is particularly known for its high recurrence rates. Here, we present a case of a recurrent tenosynovial giant cell tumour of the flexor tendon sheath of the index finger at the distal palmar crease. Diagnosis was confirmed by MRI and the lesion was excised. Histopathology revealed a localized type of tenosynovial giant cell tumour.

An unusual presentation of diffuse tenosynovial giant cell tumour in the neck

2003 ◽  
Vol 43 (4) ◽  
pp. 393-396 ◽  
Author(s):  
G Pillai ◽  
M Nicolas ◽  
K Lwin ◽  
F Pezzella ◽  
K Gatter
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Unusual Presentation ◽  
Tenosynovial Giant Cell Tumour

Treatment of tenosynovial giant-cell tumour types

2019 ◽  
Vol 20 (8) ◽  
pp. e399
Author(s):  
Yoshihiro Nishida ◽  
Kunihiro Ikuta
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Tenosynovial Giant Cell Tumour
Sign in / Sign up

Export Citation Format

Share Document